Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $4.6 million.

  • Corcept Therapeutics' Other Operating Expenses rose 6030.69% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 3657.04%. This contributed to the annual value of $14.0 million for FY2022, which is N/A changed from last year.
  • Per Corcept Therapeutics' latest filing, its Other Operating Expenses stood at $4.6 million for Q3 2025, which was up 6030.69% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Other Operating Expenses registered a high of $4.6 million during Q3 2025, and its lowest value of $1.2 million during Q1 2022.
  • For the 5-year period, Corcept Therapeutics' Other Operating Expenses averaged around $2.0 million, with its median value being $1.6 million (2023).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first plummeted by 3248.14% in 2021, then surged by 8290.04% in 2024.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Other Operating Expenses stood at $1.4 million in 2021, then rose by 9.31% to $1.5 million in 2022, then rose by 26.82% to $1.9 million in 2023, then surged by 57.49% to $3.0 million in 2024, then skyrocketed by 55.48% to $4.6 million in 2025.
  • Its Other Operating Expenses was $4.6 million in Q3 2025, compared to $3.4 million in Q2 2025 and $2.4 million in Q1 2025.